A 10 week open-label pilot study to evaluate the effectiveness and safety of memantine (Namenda) as augmentation therapy in patients with generalized anxiety disorder (GAD) or social anxiety disorder (SAD), who are only partial responders to selective serotonin-norepinephrine reuptake inhibitors (SNRI's) or selective serotonin reuptake inhibitors (SSRI's).

Trial Profile

A 10 week open-label pilot study to evaluate the effectiveness and safety of memantine (Namenda) as augmentation therapy in patients with generalized anxiety disorder (GAD) or social anxiety disorder (SAD), who are only partial responders to selective serotonin-norepinephrine reuptake inhibitors (SNRI's) or selective serotonin reuptake inhibitors (SSRI's).

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2010

At a glance

  • Drugs Memantine (Primary)
  • Indications Generalised anxiety disorder; Social phobia
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Sep 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 16 Dec 2008 Planned end date (Dec 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top